Loading
A phase 2 trial of Albipagrastim alf in childhood cancers, run by Qilu Pharmaceutical Co., Ltd., now recruiting.
Phase II Study of QLC2519 in Pediatric Solid Tumor Participants is a phase 2 interventional study registered as NCT07724756 by Qilu Pharmaceutical Co., Ltd., with 18 participants planned, started 2026-06-26 and due to reach its primary completion in 2027-06-26. Interventions recorded: Albipagrastim alf.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/